Search

Your search keyword '"Pinto, Navin"' showing total 244 results
Start Over Author "Pinto, Navin"
244 results on '"Pinto, Navin"'

2. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Author

Goldsmith, Kelly C., Park, Julie R., Kayser, Kimberly, Malvar, Jemily, Chi, Yueh-Yun, Groshen, Susan G., Villablanca, Judith G., Krytska, Kateryna, Lai, Lillian M., Acharya, Patricia T., Goodarzian, Fariba, Pawel, Bruce, Shimada, Hiroyuki, Ghazarian, Susan, States, Lisa, Marshall, Lynley, Chesler, Louis, Granger, Meaghan, Desai, Ami V., Mody, Rajen, Morgenstern, Daniel A., Shusterman, Suzanne, Macy, Margaret E., Pinto, Navin, Schleiermacher, Gudrun, Vo, Kieuhoa, Thurm, Holger C., Chen, Joseph, Liyanage, Marlon, Peltz, Gerson, Matthay, Katherine K., Berko, Esther R., Maris, John M., Marachelian, Araz, and Mossé, Yael P.

Published
2023
Full Text
View/download PDF

3. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

Author

Vitanza, Nicholas A., Ronsley, Rebecca, Choe, Michelle, Henson, Casey, Breedt, Mandy, Barrios-Anderson, Adriel, Wein, Amy, Brown, Christopher, Beebe, Adam, Kong, Ada, Kirkey, Danielle, Lee, Brittany M., Leary, Sarah E.S., Crotty, Erin E., Hoeppner, Corrine, Holtzclaw, Susan, Wilson, Ashley L., Gustafson, Joshua A., Foster, Jessica B., Iliff, Jeffrey J., Goldstein, Hannah E., Browd, Samuel R., Lee, Amy, Ojemann, Jeffrey G., Pinto, Navin, Gust, Juliane, Gardner, Rebecca A., Jensen, Michael C., Hauptman, Jason S., and Park, Julie R.

Published
2023
Full Text
View/download PDF

4. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer

Author

Church, Alanna J., Corson, Laura B., Kao, Pei-Chi, Imamovic-Tuco, Alma, Reidy, Deirdre, Doan, Duong, Kang, Wenjun, Pinto, Navin, Maese, Luke, Laetsch, Theodore W., Kim, AeRang, Colace, Susan I., Macy, Margaret E., Applebaum, Mark A., Bagatell, Rochelle, Sabnis, Amit J., Weiser, Daniel A., Glade-Bender, Julia L., Homans, Alan C., Hipps, John, Harris, Haley, Manning, Danielle, Al-Ibraheemi, Alyaa, Li, Yvonne, Gupta, Hersh, Cherniack, Andrew D., Lo, Ying-Chun, Strand, Gianna R., Lee, Lobin A., Pinches, R. Seth, Lazo De La Vega, Lorena, Harden, Maegan V., Lennon, Niall J., Choi, Seong, Comeau, Hannah, Harris, Marian H., Forrest, Suzanne J., Clinton, Catherine M., Crompton, Brian D., Kamihara, Junne, MacConaill, Laura E., Volchenboum, Samuel L., Lindeman, Neal I., Van Allen, Eliezer, DuBois, Steven G., London, Wendy B., and Janeway, Katherine A.

Published
2022
Full Text
View/download PDF

5. STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.

Author

Choe, Michelle, primary, Taylor, Mallory, additional, Wendler, Jason, additional, Narayanaswamy, Prabha, additional, Rawlings-Rhea, Stephanie, additional, Seidel, Kristy, additional, Huang, Wenjun, additional, Pattabhi, Sowmya, additional, Gamble, Danielle, additional, Ho, On, additional, Wilson, Ashley, additional, Mgebroff, Stephanie, additional, Brown, Christopher, additional, Lindgren, Catherine, additional, Annesley, Colleen, additional, Gardner, Rebecca Alice, additional, Jensen, Michael, additional, Park, Julie R., additional, Albert, Catherine Michelle, additional, and Pinto, Navin, additional

Published
2024
Full Text
View/download PDF

6. Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.

Author

Vitanza, Nicholas A., Choe, Michelle, Brown, Christopher, Beebe, Adam, Kong, Ada, Rogers, Lisa, Jacob, Susan, Mano, Elena, Abuan, Kimberly, Mgebroff, Stephanie, Lindgren, Catherine, Gustafson, Joshua A., Wilson, Ashley L., Noll, Alyssa, Ronsley, Rebecca, Crotty, Erin E., Leary, Sarah E. S., Foster, Jessica B., Pinto, Navin, and Gust, Juliane

Subjects
T cells, CHIMERIC antigen receptors, TUMORS in children, CENTRAL nervous system, BRAIN tumors
Abstract

BACKGROUND: A major obstacle in translating the therapeutic potential of chimeric antigen receptor (CAR) T cells to children with central nervous system (CNS) tumors is the blood–brain barrier. To overcome this limitation, preclinical and clinical studies have supported the use of repeated, locoregional intracranial CAR T-cell delivery. However, there is limited literature available describing the process for the involvement of an investigational drug service (IDS) pharmacy, particularly in the setting of a children’s hospital with outpatient dosing for CNS tumors. OBJECTIVES: To describe Seattle Children’s Hospital’s experience in clinically producing CAR T cells and the implementation of IDS pharmacy practices used to deliver more than 300 intracranial CAR T-cell doses to children, as well as to share how we refined the processing techniques from CAR T-cell generation to the thawing of fractionated doses for intracranial delivery. METHODS: Autologous CD4+ and CD8+ T cells were collected and transduced to express HER2, EGFR, or B7-H3–specific CAR T cells. Cryopreserved CAR T cells were thawed by the IDS pharmacy before intracranial delivery to patients with recurrent/refractory CNS tumors or with diffuse intrinsic pontine glioma/diffuse midline glioma. RESULTS: The use of a thaw-and-dilute procedure for cryopreserved individual CAR T-cell doses provides reliable viability and is more efficient than typical thaw-and-wash protocols. Cell viability with the thaw-and-dilute protocol was approximately 75% and was always within 10% of the viability assessed at cryopreservation. Cell viability was preserved through 6 hours after thawing, which exceeded the 1-hour time frame from thawing to infusion. CONCLUSION: As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery. [ABSTRACT FROM AUTHOR]

Published
2024

7. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors

Author

Sehdev, Amikar, Karrison, Theodore, Zha, Yuanyuan, Janisch, Linda, Turcich, Michelle, Cohen, Ezra EW, Maitland, Michael, Polite, Blase N, Gajewski, Thomas F, Salgia, Ravi, Pinto, Navin, Bissonnette, Marc B, Fleming, Gini F, Ratain, Mark J, and Sharma, Manish R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Drug Synergism, Female, Humans, Leukocytes, Mononuclear, Male, Metformin, Middle Aged, Neoplasms, Phosphorylation, Pilot Projects, Ribosomal Protein S6 Kinases, 70-kDa, Sirolimus, TOR Serine-Threonine Kinases, Young Adult, P70S6K and mTOR, Pharmacodynamics, Solid tumors, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Pharmacology and pharmaceutical sciences
Abstract

BackgroundSirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis.MethodsPatients with advanced solid tumor were treated with sirolimus for 7 days followed by randomization to either sirolimus with metformin (Arm A) or sirolimus (Arm B) until day 21. From day 22 onwards, all patients received sirolimus and metformin. The primary aim was to compare the change in phospho-p70S6K (pp70S6K) in peripheral blood mononuclear cells (PBMC) from day 8 to day 22 using a two-sample t test. Secondary aims were objective response rate, toxicity, and other serum pharmacodynamic biomarkers (e.g., fasting glucose, triglycerides, insulin, C-peptide, IGF-1, IGF-1R, IGF-BP, and leptin).Results24 patients were enrolled, with 18 evaluable for the primary endpoint. There was no significant difference in mean change in pp70S6K in arm A vs. arm B (- 0.12 vs. - 0.16; P = 0.64). Similarly, there were no significant differences in other serum pharmacodynamic biomarkers. There were no partial responses. There were no dose-limiting or unexpected toxicities.ConclusionsAdding metformin to sirolimus, although well tolerated, was not associated with significant changes in pp70S6K in PBMC or other serum pharmacodynamic biomarkers.ImpactCombining metformin with sirolimus did not improve mTOR inhibition.

Published
2018

8. First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma

Author

Pinto, Navin, primary, Künkele, Annette, additional, Albert, Catherine, additional, Taylor, Mallory, additional, Ullom, Heidi, additional, Wilson, Ashley, additional, Huang, Wenjun, additional, Wendler, Jason, additional, Seidel, Kristy, additional, Brown, Christopher, additional, Gustafson, Joshua, additional, Rawlings-Rhea, Stephanie, additional, Beebe, Adam, additional, Mgebroff, Stephanie, additional, Gardner, Rebecca, additional, Jensen, Michael, additional, and Park, Julie, additional

Published
2024
Full Text
View/download PDF

9. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

Author

Vitanza, Nicholas A., Johnson, Adam J., Wilson, Ashley L., Brown, Christopher, Yokoyama, Jason K., Künkele, Annette, Chang, Cindy A., Rawlings-Rhea, Stephanie, Huang, Wenjun, Seidel, Kristy, Albert, Catherine M., Pinto, Navin, Gust, Juliane, Finn, Laura S., Ojemann, Jeffrey G., Wright, Jason, Orentas, Rimas J., Baldwin, Michael, Gardner, Rebecca A., Jensen, Michael C., and Park, Julie R.

Published
2021
Full Text
View/download PDF

10. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Author

Geoerger, Birgit, Kang, Hyoung Jin, Yalon-Oren, Michal, Marshall, Lynley V, Vezina, Catherine, Pappo, Alberto, Laetsch, Theodore W, Petrilli, Antonio S, Ebinger, Martin, Toporski, Jacek, Glade-Bender, Julia, Nicholls, Wayne, Fox, Elizabeth, DuBois, Steven G, Macy, Margaret E, Cohn, Susan L, Pathiraja, Kumudu, Diede, Scott J, Ebbinghaus, Scot, and Pinto, Navin

Published
2020
Full Text
View/download PDF

11. Advances in Risk Classification and Treatment Strategies for Neuroblastoma

Author

Pinto, Navin R, Applebaum, Mark A, Volchenboum, Samuel L, Matthay, Katherine K, London, Wendy B, Ambros, Peter F, Nakagawara, Akira, Berthold, Frank, Schleiermacher, Gudrun, Park, Julie R, Valteau-Couanet, Dominique, Pearson, Andrew DJ, and Cohn, Susan L

Subjects
Cancer, Pediatric Cancer, Neuroblastoma, Pediatric, Orphan Drug, Rare Diseases, Neurosciences, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, Adolescent, Age of Onset, Child, Child, Preschool, Cooperative Behavior, Diffusion of Innovation, Humans, Infant, Infant, Newborn, Interdisciplinary Communication, International Cooperation, Medical Oncology, Pediatrics, Predictive Value of Tests, Risk Assessment, Risk Factors, Survivors, Time Factors, Treatment Outcome, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and cooperative groups were disparate, limiting the ability to compare clinical trial results. To mitigate this problem and enhance collaborative research, homogenous pretreatment patient cohorts have been defined by the International Neuroblastoma Risk Group classification system. During the past 30 years, increasingly intensive, multimodality approaches have been developed to treat patients who are classified as high risk, whereas patients with low- or intermediate-risk neuroblastoma have received reduced therapy. This treatment approach has resulted in improved outcome, although survival for high-risk patients remains poor, emphasizing the need for more effective treatments. Increased knowledge regarding the biology and genetic basis of neuroblastoma has led to the discovery of druggable targets and promising, new therapeutic approaches. Collaborative efforts of institutions and international cooperative groups have led to advances in our understanding of neuroblastoma biology, refinements in risk classification, and stratified treatment strategies, resulting in improved outcome. International collaboration will be even more critical when evaluating therapies designed to treat small cohorts of patients with rare actionable mutations.

Published
2015

13. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer

Author

Lazo De La Vega, Lorena, Comeau, Hannah, Sallan, Sarah, Al-Ibraheemi, Alyaa, Gupta, Hersh, Li, Yvonne Y., Tsai, Harrison K., Kang, Wenjun, Ward, Abigail, Church, Alanna J., Kim, AeRang, Pinto, Navin R., Macy, Margaret E., Maese, Luke D., Sabnis, Amit J., Cherniack, Andrew D., Lindeman, Neal I., Anderson, Megan E., Cooney, Tabitha M., Yeo, Kee Kiat, Reaman, Gregory H., DuBois, Steven G., Collins, Natalie B., Johnson, Bruce E., Janeway, Katherine A., and Forrest, Suzanne J.

Published
2022
Full Text
View/download PDF

14. List of Contributors

Author

Ahmed, Nabil, primary, Appelbaum, Jacob S., additional, Ballen, Karen, additional, Cantilena, Cathy Conry, additional, Ceppi, Francesco, additional, Cornetta, Kenneth, additional, Curran, Kevin J., additional, Fry, Terry J., additional, Gardner, Rebecca A., additional, Gust, Juliane, additional, Gutierrez, Cristina, additional, Highfill, Steven L., additional, Jacoby, Elad, additional, Jin, Ping, additional, Joseph, Sujith K., additional, Kindwall-Keller, Tamila L., additional, Komanduri, Krishna V., additional, Lee, Daniel W., additional, Mahadeo, Kris M., additional, Molloy, Eoghan, additional, Orellana-Noia, Victor M., additional, Orentas, Rimas J., additional, Panch, Sandhya Ramanathan, additional, Park, Jae H., additional, Perica, Karlo, additional, Pinto, Navin, additional, Portell, Craig A., additional, Pulsipher, Michael A., additional, Sanber, Khaled, additional, Shah, Nirali N., additional, Shalabi, Haneen, additional, Stroncek, David, additional, Summers, Corinne, additional, Tambaro, Francesco Paolo, additional, Taraseviciute, Agne, additional, Turtle, Cameron J., additional, Varadarajan, Indumathy, additional, Wayne, Alan S., additional, and West, Kamille A., additional

Published
2020
Full Text
View/download PDF

16. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor

Author

Schienda, Jaclyn, Church, Alanna J., Corson, Laura B., Decker, Brennan, Clinton, Catherine M., Manning, Danielle K., Imamovic-Tuco, Alma, Reidy, Deirdre, Strand, Gianna R., Applebaum, Mark A., Bagatell, Rochelle, DuBois, Steven G., Glade-Bender, Julia L., Kang, Wenjun, Kim, AeRang, Laetsch, Theodore W., Macy, Margaret E., Maese, Luke, Pinto, Navin, Sabnis, Amit J., Schiffman, Joshua D., Colace, Susan I., Volchenboum, Samuel L., Weiser, Daniel A., Nowak, Jonathan A., Lindeman, Neal I., Janeway, Katherine A., Crompton, Brian D., and Kamihara, Junne

Published
2021
Full Text
View/download PDF

19. Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

20. Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

22. Abstract LB121: BrainChild-03: Intraventricular B7-H3 CAR T cells for recurrent/refractory central nervous system tumors and non-pontine diffuse midline glioma in children and young adults

Author

Vitanza, Nicholas A., primary, Gust, Juliane, additional, Ronsley, Rebecca, additional, Wilson, Ashley L., additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Albert, Catherine M., additional, Pinto, Navin, additional, Orentas, Rimas J., additional, Gardner, Rebecca A., additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2023
Full Text
View/download PDF

23. Abstract CT137: ENLIGHTen-01: a phase 1 study of fluorescein-specific (FITC-E2)-car T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma

Author

Albert, Catherine M., primary, Pinto, Navin R., additional, Taylor, Mallory, additional, Wilson, Ashley, additional, Rawlings-Rhea, Stephanie, additional, Narayanaswamy, Prabha, additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Mgebroff, Stephanie, additional, Brown, Christopher, additional, Garcia, Jacob, additional, Teoh, Jeffrey, additional, Orentas, Rimas J., additional, Gardner, Rebecca A., additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2023
Full Text
View/download PDF

24. Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, primary, Ding, Xiangming, primary, Zhang, Fan F., primary, Hibbitts, Emily, primary, Kennedy, Rebekah, primary, Tibbetts, Rachelle, primary, Wong-Michalak, Shannon, primary, Craig, David W., primary, Manojlovic, Zarko, primary, Hogarty, Michael D., primary, Kreissman, Susan, primary, Bagatell, Rochelle, primary, Irwin, Meredith S., primary, Park, Julie R., primary, and Asgharzadeh, Shahab, primary

Published
2023
Full Text
View/download PDF

25. Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Author

Vitanza, Nicholas A., primary, Wilson, Ashley L., primary, Huang, Wenjun, primary, Seidel, Kristy, primary, Brown, Christopher, primary, Gustafson, Joshua A., primary, Yokoyama, Jason K., primary, Johnson, Adam J., primary, Baxter, Blake A., primary, Koning, Ryan W., primary, Reid, Aquene N., primary, Meechan, Michael, primary, Biery, Matthew C., primary, Myers, Carrie, primary, Rawlings-Rhea, Stephanie D., primary, Albert, Catherine M., primary, Browd, Samuel R., primary, Hauptman, Jason S., primary, Lee, Amy, primary, Ojemann, Jeffrey G., primary, Berens, Michael E., primary, Dun, Matthew D., primary, Foster, Jessica B., primary, Crotty, Erin E., primary, Leary, Sarah E.S., primary, Cole, Bonnie L., primary, Perez, Francisco A., primary, Wright, Jason N., primary, Orentas, Rimas J., primary, Chour, Tony, primary, Newell, Evan W., primary, Whiteaker, Jeffrey R., primary, Zhao, Lei, primary, Paulovich, Amanda G., primary, Pinto, Navin, primary, Gust, Juliane, primary, Gardner, Rebecca A., primary, Jensen, Michael C., primary, and Park, Julie R., primary

Published
2023
Full Text
View/download PDF

26. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma

Author

Marinoff, Amanda E., primary, Spurr, Liam F., additional, Fong, Christina, additional, Li, Yvonne Y., additional, Forrest, Suzanne J., additional, Ward, Abigail, additional, Doan, Duong, additional, Corson, Laura, additional, Mauguen, Audrey, additional, Pinto, Navin, additional, Maese, Luke, additional, Colace, Susan, additional, Macy, Margaret E., additional, Kim, AeRang, additional, Sabnis, Amit J., additional, Applebaum, Mark A., additional, Laetsch, Theodore W., additional, Glade-Bender, Julia, additional, Weiser, Daniel A., additional, Anderson, Megan, additional, Crompton, Brian D., additional, Meyers, Paul, additional, Zehir, Ahmet, additional, MacConaill, Laura, additional, Lindeman, Neal, additional, Nowak, Jonathan A., additional, Ladanyi, Marc, additional, Church, Alanna J., additional, Cherniack, Andrew D., additional, Shukla, Neerav, additional, and Janeway, Katherine A., additional

Published
2023
Full Text
View/download PDF

27. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Author

Pinto, Navin, primary, Naranjo, Arlene, additional, Ding, Xiangming, additional, Zhang, Fan F., additional, Hibbitts, Emily, additional, Kennedy, Rebekah, additional, Tibbetts, Rachelle, additional, Wong-Michalak, Shannon, additional, Craig, David W., additional, Manojlovic, Zarko, additional, Hogarty, Michael D., additional, Kreissman, Susan, additional, Bagatell, Rochelle, additional, Irwin, Meredith S., additional, Park, Julie R., additional, and Asgharzadeh, Shahab, additional

Published
2023
Full Text
View/download PDF

28. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor

Author

Lerman, Benjamin J., primary, Li, Yimei, additional, Carlowicz, Cecilia, additional, Granger, Meaghan, additional, Cash, Thomas, additional, Sadanand, Arhanti, additional, Somers, Katherine, additional, Ranavaya, Aeesha, additional, Weiss, Brian D., additional, Choe, Michelle, additional, Foster, Jennifer H., additional, Pinto, Navin, additional, Morgenstern, Daniel A., additional, Rafael, Margarida Simão, additional, Streby, Keri A., additional, Zeno, Rachel N., additional, Mody, Rajen, additional, Yazdani, Sahr, additional, Desai, Ami V., additional, Macy, Margaret E., additional, Shusterman, Suzanne, additional, Federico, Sara M., additional, and Bagatell, Rochelle, additional

Published
2023
Full Text
View/download PDF

30. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Author

Vitanza, Nicholas A., primary, Wilson, Ashley L., additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Brown, Christopher, additional, Gustafson, Joshua A., additional, Yokoyama, Jason K., additional, Johnson, Adam J., additional, Baxter, Blake A., additional, Koning, Ryan W., additional, Reid, Aquene N., additional, Meechan, Michael, additional, Biery, Matthew C., additional, Myers, Carrie, additional, Rawlings-Rhea, Stephanie D., additional, Albert, Catherine M., additional, Browd, Samuel R., additional, Hauptman, Jason S., additional, Lee, Amy, additional, Ojemann, Jeffrey G., additional, Berens, Michael E., additional, Dun, Matthew D., additional, Foster, Jessica B., additional, Crotty, Erin E., additional, Leary, Sarah E.S., additional, Cole, Bonnie L., additional, Perez, Francisco A., additional, Wright, Jason N., additional, Orentas, Rimas J., additional, Chour, Tony, additional, Newell, Evan W., additional, Whiteaker, Jeffrey R., additional, Zhao, Lei, additional, Paulovich, Amanda G., additional, Pinto, Navin, additional, Gust, Juliane, additional, Gardner, Rebecca A., additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2022
Full Text
View/download PDF

32. Abstract 3893: Rare FGFR oncogenic alterations in sequenced pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer

Author

Vega, Lorena Lazo De La, primary, Church, Alanna J., additional, Comeau, Hannah, additional, Kang, Wenjun, additional, Kim, AeRang, additional, Pinto, Navin R., additional, Macy, Margaret E., additional, Maese, Luke D., additional, DuBois, Steven G., additional, Johnson, Bruce E., additional, Janeway, Katherine A., additional, and Forrest, Suzanne J., additional

Published
2022
Full Text
View/download PDF

34. Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

Author

Desai, Ami V., primary, Applebaum, Mark A., additional, Karrison, Theodore G., additional, Oppong, Akosua, additional, Yuan, Cindy, additional, Berg, Katherine R., additional, MacQuarrie, Kyle, additional, Sokol, Elizabeth, additional, Hall, Anurekha G., additional, Pinto, Navin, additional, Wolfe, Ian, additional, Mody, Rajen, additional, Shusterman, Suzanne, additional, Smith, Valeria, additional, Foster, Jennifer H., additional, Nassin, Michele, additional, LaBelle, James L., additional, Bagatell, Rochelle, additional, and Cohn, Susan L., additional

Published
2022
Full Text
View/download PDF

36. Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.

Author

Chi, Susan N., primary, Bourdeaut, Franck, additional, Casanova, Michela, additional, Kilburn, Lindsay Baker, additional, Hargrave, Darren R., additional, McCowage, Geoffrey Brian, additional, Pinto, Navin R., additional, Yang, Jay, additional, Chadha, Raminder, additional, Kahali, Bhaskar, additional, Tapia, Coya, additional, and Nysom, Karsten, additional

Published
2022
Full Text
View/download PDF

37. Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Author

Cash, Thomas, primary, Marachelian, Araz, additional, DuBois, Steven G., additional, Chi, Yueh-Yun, additional, Groshen, Susan G., additional, Shamirian, Anasheh, additional, Stout, Alina C, additional, Macy, Margaret E, additional, Pinto, Navin R., additional, Desai, Ami Vijay, additional, Sondel, Paul M., additional, Asgharzadeh, Shahab, additional, Weiss, Brian D., additional, Mosse, Yael P., additional, Matthay, Katherine K., additional, Park, Julie R., additional, and Goldsmith, Kelly C., additional

Published
2022
Full Text
View/download PDF

38. STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.

Author

Pinto, Navin R., primary, Albert, Catherine Michelle, additional, Taylor, Mallory, additional, Wilson, Ashley, additional, Rawlings-Rhea, Stephanie, additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Narayanaswany, Prabha, additional, Wu, Vicky, additional, Brown, Christopher, additional, Vitanza, Nicholas A., additional, Orentas, Rimas, additional, Gardner, Rebecca Alice, additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2022
Full Text
View/download PDF

39. STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.

Author

Albert, Catherine Michelle, primary, Pinto, Navin R., additional, Taylor, Mallory, additional, Wilson, Ashley, additional, Rawlings-Rhea, Stephanie, additional, Mgebroff, Stephanie, additional, Brown, Christopher, additional, Lindgren, Catherine, additional, Huang, Wenjun, additional, Seidel, Kristy, additional, Narayanaswany, Prabha, additional, Wu, Vicky, additional, Rudzinski, Erin R., additional, Vitanza, Nicholas A., additional, Gust, Juliane, additional, Gardner, Rebecca Alice, additional, Jensen, Michael C., additional, and Park, Julie R., additional

Published
2022
Full Text
View/download PDF

40. IMMU-09. Interim analysis from BrainChild-03: Seattle Children’s Locoregional B7-H3 CAR T Cell Trial for Children with Recurrent Central Nervous System Tumors and DIPG

Author

Vitanza, Nicholas, primary, Gust, Juliane, additional, Wilson, Ashley, additional, Huang, Wenjun, additional, Chen, Dickson, additional, Meechan, Michael, additional, Biery, Matt, additional, Myers, Carrie, additional, Tahiri, Sophie, additional, Crotty, Erin, additional, Leary, Sarah, additional, Cole, Bonnie, additional, Browd, Samuel, additional, Hauptman, Jason, additional, Lee, Amy, additional, Albert, Catherine, additional, Pinto, Navin, additional, Orentas, Rimas, additional, Gardner, Rebecca, additional, Jensen, Michael, additional, and Park, Julie, additional

Published
2022
Full Text
View/download PDF

41. Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.

Author

DeNardo, Bradley, primary, Foster, Jennie, additional, Pinto, Navin R., additional, Saulnier Sholler, Giselle Linda, additional, Vo, Kieuhoa Tran, additional, Desai, Ami Vijay, additional, Sun, Jessica, additional, Wagner, Lars M., additional, Macy, Margaret E, additional, Mody, Rajen, additional, Oesterheld, Javier E., additional, Cash, Thomas, additional, Bhuta, Roma, additional, Barbieri, Eveline, additional, Pearson, Andrew DJ, additional, Cavalcante, Ludimila, additional, Giles, Francis J., additional, and Lulla, Rishi Ramesh, additional

Published
2022
Full Text
View/download PDF

42. CTIM-27. LOCOREGIONAL B7-H3-SPECIFIC CAR T CELLS FOR CHILDREN AND YOUNG ADULTS WITH DIPG: INTERIM REPORT OF BRAINCHILD-03 ARM C

Author

Vitanza, Nicholas, primary, Wilson, Ashley, additional, Yokoyama, Jason, additional, Johnson, Adam, additional, Gust, Jule, additional, Huang, Wenjun, additional, Albert, Catherine, additional, Pinto, Navin, additional, Foster, Jessica, additional, Orentas, Rimas, additional, Paulovich, Amanda, additional, Berens, Michael, additional, Gardner, Rebecca, additional, Jensen, Michael, additional, and Park, Julie, additional

Published
2021
Full Text
View/download PDF

43. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

Author

DuBois, Steven G., primary, Granger, M. Meaghan, additional, Groshen, Susan, additional, Tsao-Wei, Denice, additional, Ji, Lingyun, additional, Shamirian, Anasheh, additional, Czarnecki, Scarlett, additional, Goodarzian, Fariba, additional, Berkovich, Rachel, additional, Shimada, Hiroyuki, additional, Villablanca, Judith G., additional, Vo, Kieuhoa T., additional, Pinto, Navin, additional, Mosse, Yael P., additional, Maris, John M., additional, Shusterman, Suzanne, additional, Cohn, Susan L., additional, Goldsmith, Kelly C., additional, Weiss, Brian, additional, Yanik, Gregory A., additional, Twist, Clare J., additional, Irwin, Meredith S., additional, Haas-Kogan, Daphne A., additional, Park, Julie R., additional, Marachelian, Araz, additional, and Matthay, Katherine K., additional

Published
2021
Full Text
View/download PDF

44. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence

Author

Pinto, Navin, Mayfield, Jodi R., Raca, Gordana, Applebaum, Mark A., Chlenski, Alexandre, Sukhanova, Madina, Bagatell, Rochelle, Irwin, Meredith S., Little, Anthony, Rawwas, Jawhar, Gosiengfiao, Yasmin, Delattre, Olivier, Janoueix-Lerosey, Isabelle, Lapouble, Eve, Schleiermacher, Gudrun, and Cohn, Susan L.

Published
2016
Full Text
View/download PDF

50. IMMU-11. CLINICAL UPDATES AND CORRELATIVE FINDINGS FROM THE FIRST PATIENT WITH DIPG TREATED WITH INTRACRANIAL CAR T CELLS

Author

Vitanza, Nicholas, primary, Wilson, Ashley, additional, Gust, Juliane, additional, Huang, Wenjun, additional, Perez, Francisco, additional, Albert, Catherine, additional, Pinto, Navin, additional, Gardner, Rebecca, additional, Orentas, Rimas, additional, Berens, Michael, additional, Jensen, Michael, additional, and Park, Julie, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results